Zymeworks Inc., of Vancouver, British Columbia, said Daiichi Sankyo Co. Ltd., of Tokyo, exercised its option for a commercial license to an immuno-oncology bispecific built on Zymeworks' Azymetric and Efect platforms. Zymeworks said it expects to receive a $3.5 million milestone payment based on Daiichi Sankyo's selection of the first of up to three lead candidates under collaboration agreements between the companies.